IRIS
International Randomized Study of Interferon and STI571
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 1,106 patients with newly diagnosed chronic-phase CML, imatinib improved cytogenetic response and progression-free survival compared with interferon-α + cytarabine.
N
1.106
Design
Open-label RCT
Endpunkt
18-month cytogenetic response
Relevanz
1
Ergebnis18-mo cytogenetic response 76.2% vs 14.5%. 10-yr OS 83.3%; 10-yr complete cytogenetic response in 82.8%.
O'Brien SG, et al. N Engl J Med. 2003;348(11):994-1004; Hochhaus A, et al. N Engl J Med. 2017;376(10):917-927. 10.1056/NEJMoa022457
Diskussion & Kritik
Transformed CML from a uniformly fatal disease to one with near-normal life expectancy. Foundation for the entire BCR-ABL TKI class.